Employers play a bigger role in pensions than imagined October 5, 2026 Every link in the pension chain – from trustees to consultants to employers – has a part to play, writes Lady Mayor Susan Langley For many UK savers, their pension pot will become their single largest asset, bigger than their home. Yet too often the industry loses savers from the conversation entirely between the moment [...]
KBRA Assigns Preliminary Ratings for RRE 11 Loan Management DAC (Reset) October 2, 2026 KBRA UK (KBRA) assigns preliminary ratings to five classes of refinancing Notes issued by RRE 11 Loan Management DAC, a cash flow collateralised loan obligation (CLO) backed primarily by a diversified portfolio of Euro-denominated corporate loans. RRE 11 Loan Management DAC is managed by Redding Ridge Asset Management (UK) LLP (“RRAM UK” or the “collateral [...]
London is running out of development land for sport teams to build stadiums on October 2, 2026 One of London’s greatest assets is its varied and wide-ranging sports scene; six Premier League football clubs, many further down the pyramid; iconic rugby, tennis and cricket grounds; indoor arenas as far as the eye can see. But with success comes a desire to expand and grow. Chelsea are actively assessing options for a new [...]
Why the tie is making a comeback October 2, 2026 Once viewed as stuffy and outdated, the tie is staging a comeback. adam bloodworth explores how the corporate staple is being reclaimed by musicians and London’s underground club scene For generations of men, the tie was something you wore without thinking. Slipping one on was simply part of your morning routine, as mundane as shaving [...]
UL Solutions Inc. Completes Acquisition of Eurofins Scientific’s Electrical & Electronics Business October 1, 2026 UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced it has completed the acquisition of the electrical and electronics (E&E) business of Eurofins Scientific SE. “This acquisition extends our 132-year commitment to our mission of working for a safer world,” said President and CEO Jennifer Scanlon. “We are thrilled to [...]
On this day: Concorde first breaks the sound barrier October 1, 2026 On this day, the 1st October, in 1969, Concorde first showed off its real party trick - breaking the sound barrier, writes Eliot Wilson.
Moody’s Analytics and Allvue Launch Credit Risk Model to Identify Early Signs of Borrower Stress in Private Credit October 1, 2026 Moody’s Analytics EDF-X Private Credit Model, powered by Allvue data, gives investors and lenders an earlier view of borrower stress in a rapidly growing market
MidOcean Concludes 2026 Equity Raise, Securing More Than $4 Billion of Equity Commitments to Accelerate Global LNG Growth Strategy October 1, 2026 MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced the conclusion of its 2026 equity capital raise, securing more than $4 billion of closed and pending commitments over the last 12 months from new strategic and institutional investors, as well as significant re-ups from existing [...]
Airtel Money set for £5.3bn valuation in London’s biggest IPO in years October 1, 2026 Airtel Money is set to float at a valuation of £5.3bn in what would be one of the biggest listings on the London Stock Exchange in recent years. The fintech arm of the telecommunications giant Airtel Africa said its investors would sell 270m shares at a price of £1.96 per share in the offer, which [...]
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab October 1, 2026 Late-breaking results from the Phase 3b ADlong clinical study presented by Almirall at EADV 2026 show treatment outcomes over time with up to five years of lebrikizumab treatment in moderate-to-severe atopic dermatitis: sustained efficacy and safety demonstrated by 92.9% of patients achieving EASI-75 and 73.8% achieving EASI-90 at the end of the study (week 108)1. At week 108 of continuous treatment, 66.7% of patients achieved clear or almost-clear skin, while 78.0% reported an absolute pruritus score of four or less on the Pruritus Numerical Rating Scale1, indicating low levels of itch, one of the most bothersome symptoms for patients. The ADlong study reflects the ongoing commitment to generating long-term evidence for lebrikizumab and the opportunity to achieve long-term disease control in AD treatment. Almirall’s scientific presence at EADV 2026 includes more than 20 abstracts across atopic dermatitis, psoriasis and actinic keratosis, alongside three expert-led events: two symposia and an interactive AD Morning Hub.